2108

PhosphoPlus[®] Estrogen Receptor α (Ser167) Antibody Duet



Orders:	877-616-CELL (2355 orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

UniProt ID: #P03372	Entrez-Gene Id: 2099				
Product Includes		Product #	Quantity	Mol. Wt	Isotype/Source
Phospho-Estrogen R	eceptor α (Ser167) (D1A3) Rabbit mAb	5587	100 µl	66 kDa	Rabbit IgG
Estrogen Receptor a	(D8H8) Rabbit mAb	8644	100 µl	66 kDa	Rabbit IgG

Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.

Description	PhosphoPlus [®] Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.
Storage	Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Background	Estrogen receptor α (ERα), a member of the steroid receptor superfamily, contains highly conserved DNA binding and ligand binding domains (1). Through its estrogen-independent and estrogen-dependent activation domains (AF-1 and AF-2, respectively), ERα regulates transcription by recruiting coactivator proteins and interacting with general transcriptional machinery (2). Phosphorylation at multiple sites provides an important mechanism to regulate ERα activity (3-5). Ser104, 106, 118, and 167 are located in the amino-terminal transcription activation function domain AF-1, and phosphorylation of these serine residues plays an important role in regulating ERα activity. Ser118 may be the substrate of the transcription regulatory kinase CDK7 (5). Ser167 may be phosphorylated by p90RSK and Akt (4,6). According to the research literature, phosphorylation at Ser167 may confer tamoxifen resistance in breast cancer patients (4).
Background References	1. Mangelsdorf, D.J. et al. (1995) <i>Cell</i> 83, 835-9. 2. Glass, C.K. and Rosenfeld, M.G. (2000) <i>Genes Dev</i> 14, 121-41. 3. Chen, D. et al. (1999) <i>Mol Cell Biol</i> 19, 1002-15. 4. Campbell, R.A. et al. (2001) <i>J Biol Chem</i> 276, 9817-24. 5. Chen, D. et al. (2000) <i>Mol Cell</i> 6, 127-37.
	6. Joel, P.B. et al. (1998) <i>Mol Cell Biol</i> 18, 1978-84.
Trademarks and Patents	6. Joel, P.B. et al. (1998) <i>Mol Cell Biol</i> 18, 1978-84. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Trademarks and Patents	
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Trademarks and Patents Limited Uses	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. PhosphoPlus is a registered trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.